Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|4|4|291-296

ISSN： 1389-4501

Source： Current Drug Targets, Vol.4, Iss.4, 2003-05, pp. : 291-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endoglin-Targeted Cancer Therapy

By  

Current Drug Delivery, Vol. 8, Iss. 1, 2011-01 ,pp. : 135-143

Bentham Science Publishers

Access to resources Recommend Favorite

Transient Injury-Dependent Up-Regulation of CD105 and its Specific Targeting with an Anti-Vascular Anti-Mouse Endoglin-Nigrin b Immunotoxin

By  

Medicinal Chemistry, Vol. 8, Iss. 6, 2012-11 ,pp. : 996-1002

Bentham Science Publishers

Access to resources Recommend Favorite

Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy

By  

Current Pharmaceutical Design, Vol. 8, Iss. 22, 2002-10 ,pp. : 1959-1972

Bentham Science Publishers

Access to resources Recommend Favorite

ADAM10 as a Target for Anti-Cancer Therapy

By  

Current Pharmaceutical Biotechnology, Vol. 9, Iss. 1, 2008-02 ,pp. : 2-8

Bentham Science Publishers

Access to resources Recommend Favorite

Target-based Anti-angiogenic Therapy in Breast Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-09 ,pp. : 4244-4257

Bentham Science Publishers

Access to resources Recommend Favorite